Everolimus makes splash in lung, GI neuroendocrine tumors
October 6, 2015|Oncology Practice
Author and Disclosure Information
AT THE EUROPEAN CANCER CONGRESS 2015
The safety profile was consistent with the known profile of everolimus, he said. In the everolimus arm, the most common drug-related adverse events of any grade were stomatitis (63%), diarrhea (31%), fatigue (31%), and infections (29%). Common grade 3/4 events were stomatitis (9%), diarrhea (7%), infections (7%), and fatigue (3%).
Dr. Peter Naredi, scientific cochair of the congress, commented that this year’s meeting is particularly exciting for clinicians treating patients with neuroendocrine tumors because two trials, RADIANT-4 and NETTER-1 both show positive results.
On Twitter @pwendl
